COVID-19 Global Drug Repurposing Study

 

(GDR Study)

Applying Network Medicine to repurpose existing FDA approved drugs to treat COVID-19, influence health policy, and update clinical guidelines

 
 
 

COVID-19 (the disease) presents a unique challenge.

SARS-CoV-2 (virus causing the disease) is complex, spreads rapidly, and the varied outcomes of COVID-19 cases challenge what current clinical research is equipped to handle.

There is a long road ahead to update policy and clinical guidelines, approve novel treatments, develop effective vaccines, and manufacture enough to distribute around the world.

Repurposed existing drugs in addition to updated global health policy and clinical guidelines will be essential for limiting the social and economic devastation caused by this virus.

long road.png
 
brigham logo.png

The GDR study is spearheaded by researchers at Brigham and Women's Hospital, one of Harvard Medical School’s flagship teaching hospitals.

 
partner logos.png

Our partner, Karolinska Institutet and Karolinska University Hospital in Sweden, whose Nobel Assembly decides the Nobel prize in Medicine and Physiology, is committed to lead the European branch of the study.

The study also has the full support of the European University Hospital Alliance (EUHA) which represents flagship university hospital systems and affiliated research centers of excellence across Europe and Great Britain.

nma logo.png

And other distinguished Network Medicine Alliance members and affiliates will contribute additional scale, capabilities, and an international presence to the COVID-19 GDR Study.

 
 

GDR Study Key Questions

1) Which contributing biological and environmental factors are protective or detrimental to an individual's response to SARS-CoV-2 infection? And how do combinations of such factors explain the varied clinical outcomes observed which range from asymptomatic to severely ill requiring hospitalization?

2) How can updated policies and clinical guidelines lessen the socioeconomic burden on society?

3) Which currently available drugs or combinations would  be most effective when repurposed to treat specific patient groups? 

 
 

Executive Committee

 

Joseph Loscalzo, MD, PhD

Chairman BOD and Scientific Committee of the Foundation and Head of Consortium and Hersey Professor of the Theory and Practice of Medicine, Soma Weiss, MD, Distinguished Chair in Medicine: Harvard Medical School.  Chairman, Department of Medicine and Physician-in-Chief: Brigham and Women’s Hospital, USA 

Jean-Luc Balligand, MD, PhD

President of Experimental and Clinical Research UC Louvain, Professor of cardiovascular physiology and pharmacology, Physician at Cliniques Universitaire Saint-luc, Universite` Catholique de Louvain (UC Louvain), Belgium

Albert-Laszlo Barabasi, PhD

Robert Gray Dodge Professor of Network Science, Distinguished University Professor, Director of Center for Complex Network Research, Dept. Of Physics, Northeastern University, Channing Division of Network Medicine, Brigham and Women’s Hospital, Harvard Medical School, USA, Director Network and Data Science, Central European University, Hungary 

Jan Baumbach, PhD

Professor and Chair of Experimental Bioinformatic, Director of Information Technology (ITW), TUM School of Life Sciences (WZW), Technical University of Munich (TUM), Germany 

Sebastiano Filetti, MD

Professor of Medicine, Delegate for "International Relations Health Care”, Sapienza Università di Roma, Italy 

Eugenio Gaudio, MD 

Rettore of the Università, Professor of Medicine, Sapienza Università di Roma, Italy 

Paolo Parini, MD, PhD

Professor, Senior Consultant, Director of Research & Development, Education and Innovation, Head of Inflammation and Infection, Karolinska University Hospital, Department of Medicine Karolinska Institutet at Huddinge University Hospital, Sweden

Enrico Petrillo, MD

Executive Director of the International Network Medicine Foundation and Consortium, Advisor to Chairman, Department of Medicine and Physician-in-Chief for International Research, Lead Investigator, Division of General Internal Medicine, Brigham and Women’s Hospital, Lecturer, Harvard Medical School, USA

Edwin Kepner Silverman, MD, PhD

Professor Harvard Medical School, Chief of The Channing Division of Network Medicine, Brigham and Women's Hospital, Physician Pulmonary and Critical Care Medicine, Harvard Medical School, USA

 
 
wave+color+website+banner.jpg

COVID-19

The patient registry and advanced analytic capabilities implemented for this study will lead to publications, public health policies, and updated clinical guidelines to help COVID-19 patients around the world.

wave+color+website+banner.jpg

AND FUTURE global health threats

These new capabilities will have a lasting effect on the medical community leaving us better equipped to address future global health threats.

 
 
 

IF YOU ARE INTERESTED TO LEARN MORE OR WOULD CONSIDER SPONSORING THE STUDY, PLEASE EMAIL PROFESSORS ENRICO PETRILLO OR PAOLO PARINI FOR MORE INFORMATION.